Ipivivint - CAS 1481617-15-5

Ipivivint, a first-in-class, orally active and potent CDC-like kinase (CLK) inhibitor, inhibits CLK1 (IC50=1.4 μM), CLK2 (IC50=0.002 μM) and CLK3 (IC50=0.022 μM) . Ipivivint reduces Wnt pathway signaling gene expression through inhibiting CLK activity and serine and arginine rich splicing factor (SRSF) phosphorylation and disrupting spliceosome activity. Ipivivint can be used for the research of cancer[1].

Others, Wnt/beta-catenin, CDK

Cell Cycle/Checkpoint, Others, Stem Cells, Cytoskeletal Signaling

1481617-15-5

C26H21FN8

464.5

CN(C)Cc1cncc(c1)-c1cnc2[nH]nc(-c3nc4cncc(-c5cccc(F)c5)c4[nH]3)c2c1

-20°C

Ice Packs

Small Compound